Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
100ATGB
AAV5
AAV5-hFVIII-SQ
ER stress
endoplasmic reticulum
gene therapy
hemophilia A
hybrid liver-specific promoter
molecular chaperone
valoctocogene roxaparvovec
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
11 Sep 2020
11 Sep 2020
Historique:
received:
06
04
2020
accepted:
06
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Adeno-associated virus 5 (AAV5)-human factor VIII-SQ (hFVIII-SQ; valoctocogene roxaparvovec) is an AAV-mediated product under evaluation for treatment of severe hemophilia A, which contains a B-domain-deleted hFVIII (hFVIII-SQ) transgene and a hybrid liver-specific promotor (HLP). To increase FVIII-SQ expression and reduce the vector dose required, a stronger promoter may be considered. However, because FVIII-SQ is a protein known to be difficult to fold and secrete, this could potentially induce endoplasmic reticulum (ER) stress. We evaluated the effect of two AAV5-hFVIII-SQ vectors with different liver-specific promoter strength (HLP << 100ATGB) on hepatic ER stress in mice. Five weeks after receiving vehicle or vector, the percentage of transduced hepatocytes and levels of liver hFVIII-SQ DNA and RNA increased dose dependently for both vectors. At lower doses, plasma hFVIII-SQ protein levels were higher for 100ATGB. This difference was attenuated at the highest dose. For 100ATGB, liver hFVIII-SQ protein accumulated dose dependently, with increased expression of ER stress markers at the highest dose, suggesting hepatocytes reached or exceeded their capacity to fold/secrete hFVIII-SQ. These data suggest that weaker promoters may require relatively higher doses to distribute expression load across a greater number of hepatocytes, whereas relatively stronger promoters may produce comparable levels of FVIII in fewer hepatocytes, with potential for ER stress.
Identifiants
pubmed: 32775496
doi: 10.1016/j.omtm.2020.07.005
pii: S2329-0501(20)30154-6
pmc: PMC7397702
doi:
Types de publication
Journal Article
Langues
eng
Pagination
620-630Informations de copyright
© 2020 The Authors.
Références
Mol Ther. 2015 Jan;23(1):192-201
pubmed: 25322757
Lancet. 2016 Jul 9;388(10040):187-97
pubmed: 26897598
J Clin Med. 2019 Oct 26;8(11):
pubmed: 31717752
PLoS One. 2012;7(12):e51290
pubmed: 23236464
Biochem Soc Trans. 2014 Dec;42(6):1752-5
pubmed: 25399601
Sci Rep. 2017 Mar 22;7:45033
pubmed: 28327546
Toxicol Appl Pharmacol. 2015 Mar 15;283(3):157-67
pubmed: 25620058
Mol Cell Proteomics. 2015 May;14(5):1400-10
pubmed: 25724911
Dis Markers. 2015;2015:814670
pubmed: 26265795
Int J Mol Med. 2018 Apr;41(4):2233-2242
pubmed: 29393386
Mol Cell Proteomics. 2014 Dec;13(12):3698-708
pubmed: 25360005
Arch Ophthalmol. 2012 Jan;130(1):9-24
pubmed: 21911650
Mol Ther Methods Clin Dev. 2016 Sep 28;3:16064
pubmed: 27738645
Blood. 2013 Feb 7;121(6):1039-48
pubmed: 23243272
N Engl J Med. 2017 Dec 28;377(26):2519-2530
pubmed: 29224506
Int J Clin Exp Pathol. 2018 Nov 01;11(11):5223-5231
pubmed: 31949602
Cell Rep. 2018 Oct 2;25(1):212-223.e4
pubmed: 30282030
J Biol Chem. 1999 Nov 12;274(46):32539-42
pubmed: 10551804
Ann Intern Med. 2019 Oct 15;171(8):540-546
pubmed: 31499529
PLoS One. 2010 Sep 29;5(9):
pubmed: 20927376
Blood. 2004 May 1;103(9):3412-9
pubmed: 14726380
J Proteome Res. 2006 Feb;5(2):277-86
pubmed: 16457593
Blood. 2013 Apr 25;121(17):3335-44
pubmed: 23426947
Mol Ther. 2018 Feb 7;26(2):496-509
pubmed: 29292164
Blood Adv. 2019 Mar 12;3(5):825-838
pubmed: 30862611
Sci Rep. 2018 Aug 15;8(1):12179
pubmed: 30111770
Hepatology. 2011 Jul;54(1):229-39
pubmed: 21503947
Nat Cell Biol. 2000 Jun;2(6):326-32
pubmed: 10854322
Mol Ther. 2018 Oct 3;26(10):2337-2356
pubmed: 30093306
Methods Enzymol. 2011;490:71-92
pubmed: 21266244
Blood. 2020 May 21;135(21):1899-1911
pubmed: 32128578
N Engl J Med. 2014 Nov 20;371(21):1994-2004
pubmed: 25409372
J Thromb Haemost. 2014 Jan;12(1):36-42
pubmed: 24118899
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18525-30
pubmed: 19011102
Arthritis Rheum. 2004 Apr;50(4):1164-71
pubmed: 15077298
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7429-32
pubmed: 2120699
N Engl J Med. 2020 Jan 2;382(1):29-40
pubmed: 31893514
Nat Med. 2006 Mar;12(3):342-7
pubmed: 16474400
Genes Dev. 1989 Jul;3(7):1019-25
pubmed: 2570734
Mol Ther Methods Clin Dev. 2016 Sep 28;3:16063
pubmed: 27738644
Oncotarget. 2017 Mar 21;8(12):19354-19364
pubmed: 28423613
Mol Ther Methods Clin Dev. 2016 Mar 16;3:16002
pubmed: 27014711
Mol Ther. 2012 Oct;20(10):1968-80
pubmed: 22692499